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France; and 5IRSET, Rennes, FranceBackground: B-cell lymphoproliferative disorders with renal involvement are relatively frequent, but
remain poorly described. A kidney biopsy is usually required to detect the renal lesions that are often
missed using other diagnostic tools.
Methods: We retrospectively identified 34 patients with renal lymphoma diagnosed by percutaneous
kidney biopsy (PKB) at Rennes University Hospital and its affiliated hospital centers between January 1,
2004, and May 1, 2016. Clinical, biological, radiological, and histological characteristics were collected at
biopsy time.
Results: The included patients had Waldenström macroglobulinemia (n ¼ 12; 35.3%), chronic lymphocytic
leukemia/lymphocytic lymphoma (n ¼ 10; 29.5%), high-grade B-cell lymphoma (n ¼ 6; 17.6%), and
low-grade B-cell lymphoma (n ¼ 6; 17.6%). The median follow-up was 29 months. Renal involvement led to
renal function impairment in 29 patients (85.3%), among whom 20 had acute kidney injury (70%), and to
nephrotic syndrome in 4 patients (11.8%). Only 13 patients (38.2%) presented morphological kidney
anomalies among whom 5 showed bilateral infiltration. Histologically, interstitial infiltrate (97.1%) was the
most common kidney lesion, and 9 patients (26.5%) had specific lymphomatous intraglomerular lesions.
After hematological treatment (n ¼ 29), a renal response was observed only in 8 patients (27.6%).
Conclusion: Renal involvement in the context of B-cell lymphoproliferative disorders is not uncommon.
PKB is the best method to confirm this diagnosis. It should be performed early to rapidly initiate the
hematological treatment to preserve kidney function.
Kidney Int Rep (2019) 4, 688–697; https://doi.org/10.1016/j.ekir.2019.02.008
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ifferently from renal diseases associated with
monoclonal gammopathy, renal impairment in the
context of B-cell lymphoproliferative disorders remains
poorly described. In patients with such disorders, all
areas of the renal parenchyma may be affected through
different mechanisms: specific tumor infiltration,
obstructive mechanism, tubulopathy related to hyper-
calcemia, light/heavy-chain deposition disease, direct
immuno-chemotherapy toxicity, or lysis syndrome.1,2
The first reports of renal involvement in B-cell lympho-
proliferative disorders mainly concerned patients with
chronic lymphocytic leukemia, and underlined the as-
sociation between lymphomatous infiltration and
dysfunction of the affected organ/tissue.3,4 In 1980,spondence: Cécile Vigneau, CHU de Rennes, Service de
ologie, 2 Rue H Le Guilloux, Rennes, F-35033, France.
l: Cecile.vigneau@chu-rennes.fr
ved 21 November 2018; revised 28 January 2019; accepted 4
ary 2019; published online 12 February 2019Coggins2 described the first biopsy-proven case of a pa-
tient with lymphoma and renal involvement. Since
then, few cases and small series of kidney biopsies
showing lymphoma-related kidney lesions have been
reported in the literature.5–8 Recent studies described
48 patients with renal involvement in a large cohort
of patients with chronic lymphocytic leukemia and
monoclonal B-cell lymphocytosis, and 35 patients
with kidney disease associated with monoclonal IgM-
secreting B-cell lymphoproliferative disorders or more
recently 57 cases of monoclonal gammopathy-related
kidney lesions.9–11 These authors stressed the need of
more studies on kidney impairment in B-cell lympho-
proliferative disorders. Indeed, kidney involvement
in B-cell lymphoproliferative disorders is not uncom-
mon because at autopsy, renal lymphomatous infiltra-
tion has been documented in approximately one-third
of all patients with lymphoma (mostly B-cell
non-Hodgkin lymphoma).12 However, most of these
patients did not have any clinical evidence of renalKidney International Reports (2019) 4, 688–697
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was only done postmortem.12,13 Primary renal lym-
phoma without extrarenal involvement is a rare entity
and remains controversial,14,15 particularly because
kidneys do not contain lymphatic tissue. On the other
hand, kidney involvement could result from secondary
hematogenous diffusion in the case of multiorgan
involvement or invasion from adjacent retroperitoneal
lymph nodes.
Renal impairment complicates the management of
these patients and could affect the global prognosis. Its
diagnosis in patients with B-cell lymphoproliferative
disorders generally requires a kidney biopsy to detect
tumor-related lesions that frequently escape other in-
vestigations, such as computed tomography (CT) im-
aging. Therefore, we retrospectively analyzed the
clinical, biological, radiological, and histological fea-
tures of a cohort of patients with B-cell lymphoproli-
ferative disorders and biopsy-proven renal impairment
with the aim of finding clinical or laboratory parame-
ters that could predict renal involvement.PATIENTS AND METHODS
We carried out a retrospective observational study of
all patients with B-cell lymphoproliferative disorders
who had a PKB at Rennes University Hospital and in
the 3 affiliated hospital centers (Saint-Malo, Saint-
Brieuc, and Vannes) between January 1, 2004, and
May 1, 2016.
Patient Selection
As all kidney biopsies were processed and analyzed in
a single reference pathology department in Rennes,
we could perform a computerized search using the
“lymphoma” code in the central patient database for
the selected period. All the files were then reviewed to
ensure that they were complying with the 2016 World
Health Organization classification of lymphoid
neoplasms.16
The following information was collected when the
patients underwent PKB:
 Clinical data: age, sex, lymphoma type, and staging
according to the Ann Arbor classification (modified
in Cotswolds),17 comorbidities (high blood pressure,
diabetes, smoking, and dyslipidemia), performance
status, history of nephropathy with chronic kidney
disease (CKD), systemic symptoms of non-Hodgkin
lymphoma (weight loss >10% in 6 months and/or
fever >38C and/or night sweats), presence of
lymphadenopathy or extrarenal organ infiltration
(hepatomegaly, splenomegaly), symptoms of a
possible renal impairment (high blood pressure, flankKidney International Reports (2019) 4, 688–697pain, oligoanuria or edema), reasons for PKB, and
previous corticosteroid therapy.
 Biological data: kidney function assessment: serum
creatinine, serum total protein, albuminemia, cor-
rected calcium, urinalysis (particularly, leukocyturia,
hematuria, and proteinuria, completed by immuno-
electrophoresis if necessary), and immunological tests
if indicated (antineutrophil cytoplasmic antibodies,
total complement and specific complement
proteins, cryoglobulinemia); hematological assess-
ment (complete blood cell count), C-reactive protein,
serum lactate dehydrogenase, serum protein immu-
noelectrophoresis and immunofixation, flow cytom-
etry, bone marrow differential cell count, and bone
marrow aspiration and biopsy, if needed.
 Radiological data: kidney ultrasonography, CT, or
positron emission tomography–CT imaging.
Histological Examination
After fixation in Bouin’s solution, paraffin inclusion,
and staining with hematoxylin and eosin, periodic
acid-Schiff, methenamine silver–periodic acid-Schiff
(Jones’ stain), Masson trichrome, and Congo red, kid-
ney biopsies were analyzed by light microscopy.
Complementary immunofluorescence analyses were
performed with anti-IgG, -IgA, -IgM, -C3, -C4, -C1q,
-fibrinogen, -kappa and -lambda light chain antibodies.
Lymphomatous infiltration was characterized by
immunochemistry, using specific antibodies against
CD20, CD23, CD5, CD3, CD10, and cyclin D1. Ultra-
structural electron microscopy was performed for 2
samples (2 patients).
Renal and Hematological Responses to
Treatment
All available data on hematological and renal treat-
ments were collected (corticosteroids, immuno-
chemotherapy, dialysis) as well as the clinical and
laboratory changes. Acute kidney injury (AKI) was
defined as an increase of 26.2 mmol/l of serum creati-
nine in 48 hours, or by a 1.5-fold increase of the
baseline serum creatinine value in less than 7 days,
which correspond to the stage 1 of the Kidney Disease:
Improving Global Outcomes classification.18
Definition of Hematological Response
The response to the hematological treatment was clas-
sified as partial remission, complete remission (CR),
stable disease, or progressive disease, according to the
criteria described by Cheson et al.19
Definition of Renal Response
Serum level creatinine was collected at month 1 (M1),
M3, M6, M12, and the latest available follow-up. Renal689
Table 1. Patient characteristics
Variable n [ 34
Median age, yr 70 [21–88]
Sex ratio, male/female 24/10 (70.9%/29.4%)
Comorbiditiesa
HBP 17 (50.0)
Diabetes 3 (8.8)
Smoking 12 (35.3)
Dyslipidemia 8 (23.5)
Performance status
0 or 1 30 (88.2)
> 2 4 (11.8)
Lymphoma
DLBCL 6 (17.6)
Low-grade NHL 6 (17.6)
CLL/Lymphocytic lymphoma 10 (29.5)
Waldenström macroglobulinemia 12 (35.3)
Median serum creatinine (mmol/l) 215 [61–1504]
Acute kidney injury at diagnosis 20 (58.8)
Serum creatinine >300 mmol/lb 10 (50.0)
Serum creatinine > 400 mmol/lb 2 (10.0)
Biochemistry
Albuminemia, g/l 33.6  6.8
serum total protein, g/l 69.7  13.1
Corrected calcium >2.6 mmol/l 4 (11.8)
Potassium >5.5 mmol/l 5 (14.7)
Immunological analysis
ANCA 0
Complement 17
Consumedb 4 (23.5)
Cryoglobulinemia workup 13
Positiveb 3 (23.1)
Complete blood count
Cytopenia 25 (73.5)
$2b 6 (24)
Anemia <10 g/dl 17 (50.0)
Hyperlymphocytosis >4 G/l 12 (35.3)
C-reactive protein >10 mg/l 17 (50.0)
Elevated LDH 11 (32.3)
Presence of monoclonal gammopathy 16 (47.1)
Positive blood CMF 18 (52.9)
Bone marrow involvement 30
Positiveb 24 (80.0)
ANCA, anti-neutrophil cytoplasmic antibodies; CLL, chronic lymphocytic leukemia; CMF,
flow cytometry; DLBCL, diffuse large B-cell lymphoma; HBP, high blood pressure; LDH,
lactate dehydrogenase; NHL, non-Hodgkin lymphoma.
aComorbidities are not exclusives with a total value higher than 100%.
bPercentages are calculated for the subgroups.
Qualitative data: frequency (%). Quantitative data: mean  SD; median [minimum-
maximum].
CLINICAL RESEARCH L Corlu et al.: Renal Dysfunction With Direct Infiltrationresponse was defined as a glomerular filtration rate >60
ml/min estimated using the Modification of Diet in
Renal Disease equation, or not worsening of an already
present CKD. In patients with nephrotic syndrome
(defined as a proteinuria >3 g per 24 hours with
albuminemia <30 g/l), partial response was defined as a
proteinuria <3 g per 24 hours, and complete response
as a proteinuria <1 g per 24 hours. Therefore, patients
were classified as renal responders (RRs; complete þ
partial response) and renal nonresponders.690Statistical Analysis
Categorical variables were compared using the Fisher’s
exact probability test, and ordinal variables with the
Student t test. A survival curve with confidence in-
tervals was generated, and comparisons between
groups (RRs and renal nonresponders) were performed
using the Cox model. P values less than 0.05 were
considered significant. Statistical analyses were per-
formed with SAS 9.4 (SAS Inc., Cary, NC) and the
online tool “BiostaTGV,” and with R 3.3.1 for the
survival curves.
RESULTS
This study included 34 patients with renal lymphoma
diagnosed by PKB between January 1, 2004, and May
1, 2016. Indications for kidney biopsies were as fol-
lows: AKI (n ¼ 14; 41.2%), significant proteinuria (n ¼
7; 20.6%), nephrotic syndrome (n ¼ 3; 8.8%), and CKD
with known hemopathy (n ¼ 2; 5.9%). In patients with
extrarenal involvement, additional biopsies in these
other organs were not performed.
Clinical, Biological, and Radiological Findings
The patient’s characteristics at PKB are presented in
Table 1. Each subtype of B-cell lymphoproliferative
disorder was identified, and lymphoplasmacytic lym-
phoma (i.e., Waldenström macroglobulinemia) and
chronic lymphocytic leukemia were the most common
(35.3% and 29.5%, respectively). The lymphoproli-
ferative disorder was already known before the biopsy
in 21 patients (61.8%), with a median interval of 5
years (0.2–20) between the primary tumor diagnosis
and the renal involvement. The diagnosis of lympho-
proliferative disorder was made by PKB in 13 patients
(38.2%), among whom 5 underwent kidney biopsy for
a reason other than suspected lymphoma infiltration.
Thirteen patients (38.2%) had CKD higher than stage 3
before the diagnosis of renal lymphoma. Among the
clinical features (Tables 1 and 2), general signs of he-
matological disease were the most common, but some
patients reported also symptoms of kidney problems,
such as high blood pressure (35.3%), edema (35.3%),
oligoanuria (8.8%), and flank pain (2.9%), on average
2.27 months (0–9) before the PKB. No correlation be-
tween clinical symptoms and lymphoma type or renal
lesions was found. Twenty-nine (85.3%) patients had
renal dysfunction: AKI in 20 patients (69%), especially
severe AKI in 12 patients (60%) (Table 1). Patients with
non-Hodgkin lymphoma had AKI less frequently (P ¼
0.053) (Table 2). The most common urinalysis abnor-
mality was proteinuria (64.7%) mainly mixed pro-
teinuria, whereas leukocyturia was detected in only
8.8% of patients. Only the rate of nonglomerular pro-
teinuria was significantly higher in the group withKidney International Reports (2019) 4, 688–697
Table 2. Comparison according to the lymphoma types
Variable
Whole population
(n [ 34)
Waldenström macroglobulinemia
(n [ 12)
CLL/Lymphocytic Lymphoma
(n [ 10)
Low-grade NHL
(n [ 6)
DLBCL
(n [ 6) P
Renal function impairment
Yes 29 (85.3) 11 (91.7) 10 (100) 5 (83.3) 3 (50.0) 0.053
With Acute kidney injurya 20 (69) 10 (90.9) 6 (60.0) 2 (40.0) 2 (66.7) 0.193
Renal responsea 8 (27.6) 1 (9.1) 4 (40.0) 0 3 (100) 0.004
End-stage kidney diseasea 7 (24.1) 5 (45.5) 2 (20.0) 0 0 0.140
Lymphoma prior renal impairment
Yes 21 (61.8) 8 (66.7) 6 (60.0) 4 (66.7) 3 (50.0) 0.960
No 13 (38.2) 4 (33.3) 4 (40.0) 2 (33.3) 3 (50.0) 0.960
Suspected before PKBa 8 (61.5) 4 (100) 1 (25.0) 1 (50.0) 2 (66.7) 0.232
Urinary analysis
Hematuria 14 (41.2) 7 (58.3) 4 (40.0) 3 (50.0) 0 0.155
Proteinuria 22 (64.7) 11 (91.7) 6 (60) 4 (66.7) 1 (16.7) 0.017
Glomerular proteinuriaa 5 (22.7) 2 (18.2) 1 (16.7) 1 (25) 1 (100) 1.000
Mixed proteinuriaa 12 (54.6) 7 (63.6) 4 (66.6) 1 (25) 0 0.395
Overflow proteinuriaa 5 (22.7) 2 (18.2) 1 (16.7) 2 (50) 0 0.630
Nephrotic-range proteinuria 4 (11.8) 1 (8.3) 1 (10.0) 1 (16.7) 1 (16.7) 1.000
Leukocyturia 3 (8.8) 1 (8.3) 1 (10.0) 1 (16.7) 0 1.000
Kidney-related clinical features
HBP 12 (35.3) 4 (33.3) 4 (40.0) 4 (66.7) 0 0.126
Flank pain 1 (2.9) 0 0 1 (16.7) 0 0.353
Oligoanuria 3 (8.8) 2 (16.7) 1 (10.0) 0 0 0.687
Edema 12 (35.3) 6 (50.0) 4 (40.0) 1 (16.7) 1 (16.7) 0.432
Chronic kidney lesions (histology)
Interstitial 6 (17.6) 4 (33.3) 1 (10.0) 1 (16.7) 0 0.339
Tubular 17 (50.0) 8 (66.7) 6 (60.0) 2 (33.3) 1 (16.7) 0.200
Glomerular 10 (29.4) 6 (50.0) 2 (20.0) 1 (16.7) 1 (16.7) 0.301
Vascular 10 (29.4) 6 (50.0) 3 (30.0) 0 1 (16.7) 0.157
Acute kidney lesions (histology)
Interstitial 33 (971) 12 (100) 9 (90.0) 6 (100) 6 (100) 0.647
Tubular 9 (26.5) 5 (41.7) 3 (30.0) 1 (16.7) 0 0.294
Glomerular 9 (26.5) 3 (25.0) 3 (30.0) 2 (33.3) 1 (16.7) 1.000
Hematological treatment
Yes 29 (85.3) 10 (83.3) 7 (70.0) 6 (100) 6 (100) 0.201
Global response
(complete response þ partial response)a
21 (72.4) 5 (50.0) 6 (85.7) 6 (100) 4 (66.7) 0.154
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; HBP, high blood pressure; NHL, non-Hodgkin lymphoma; PKB, percutaneous kidney biopsy.
aPercentages are calculated for the subgroups.
Qualitative data: frequency (%). Significant P values are in bold.
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groups (91.7% vs 16.7%–66.7%) (P ¼ 0.017) (Table 2).
Radiological abnormalities were detected in 13 patients
(38.2%): renal tumors (n ¼ 6; 17.6%), perirenal tumors
(n ¼ 3; 8.8%), urinary tract dilation (n ¼ 2; 5.9%), and
nephromegaly (n ¼ 2; 5.9%). In 5 patients (38.5%),
these lesions were bilateral. Lymphadenopathy (61.8%)
and extranodal extension (55,9%) were observed in
32 patients. The Ann Arbor classification could be
evaluated for 12 patients, and 7 of 12 patients were
stage IV.
Kidney Biopsy Histological Analysis
Histological analysis of the kidney biopsies highlighted
the presence of diffuse (57.6%) or focal (42.4%) renal
interstitial monotypic B-cell infiltration in 33 patients
(97.1%), often associated with other renal lesions. The
other patient had chronic lymphocytic leukemia andKidney International Reports (2019) 4, 688–697granuloma without cellular infiltration. Multiple
epithelioid and gigantocellular non-necrotizing granu-
lomas were found only in patients with chronic lym-
phocytic leukemia (3 of 10) (Figure 1). Chronic tubular
lesions with atrophy/sclerosis were detected in 17 pa-
tients (50%), and acute tubular necrosis in 9 patients
(26.5%). Severe chronic ischemic lesions were found in
10 patients (29.4%). Glomerular lesions were detected
in one-third of patients with chronic ischemic lesions,
and acute glomerular lesions in 9 patients (26.5%)
(Tables 2, 3, and 4). There was no correlation between
clinical and laboratory data (particularly urinalysis
abnormalities), renal function, and histological lesions
(Table 2).
Renal and Hematological Responses
Among the 29 patients (85.3%; 5 patients did
not have any treatment) who received specific691
Figure 1. Light microscopy analysis of the kidney biopsy of a patient with CLL and granulomatous reaction. (a,b) Cortical and medullary
diffuse lymphoid infiltrate of small B cells, with focal presence of epithelioid and gigantocellular non-necrotizing granulomas (arrow; periodic
acid–Schiff). (c,d) Immunohistochemistry analysis highlighted the presence of lymphoid B cells (CD20-positive) (c) and the absence of T cells
(CD3-positive) (d).
CLINICAL RESEARCH L Corlu et al.: Renal Dysfunction With Direct Infiltrationhematological treatments, 16 showed a CR and 5 a
partial remission (Table 5). Most of the treatment
regimens included different drugs in combination
with rituximab (anti-CD20 monoclonal antibody).
Seven patients died during the treatment. Four pa-
tients with hematological CR relapsed after a median
interval of 20.5 months (1–39), and one of them died
just after the relapse. Despite the improvement of the
median serum creatinine levels after hematological
treatment initiation (219 mmol/L at M1, 153 mmol/L at
M6, and 134 mmol/L at M12), the renal response
remained poor (n ¼ 8 RR, 27.6%; n ¼ 21 renal
nonresponders, 72.4%). At the end of the follow-up,
6 patients had CKD stage 3, 10 patients CKD stage 4,
and 7 patients CKD stage 5. Among the 4 patients692with nephrotic syndrome, 3 had a CR and 1 a partial
remission after hematological treatment.
The only significant predictive factor of renal
response was the lymphoma type at diagnosis (P ¼
0.007), with 100% of RR in patients with high-grade
non-Hodgkin lymphoma versus 23.8% for the
patients with other lymphoproliferative diseases (P ¼
0.015). The median survival was 29 months (0.7–119.2)
and 12 patients (35.3%) were dead at the end of the
follow-up (Figure 2). The causes of death were hema-
tological reasons (n ¼ 5; 41.7%), end-stage renal disease
(n ¼ 3, 25%), cardiorespiratory disease (n ¼ 3, 25%),
and other malignancy (n ¼ 1, 8.3%). Mortality was
higher among renal nonresponders than RR patients
(9 vs. 1).Kidney International Reports (2019) 4, 688–697
Table 3. Acute renal glomerular lesions according to the
lymphoma type
Acute specific
glomerular lesions
Waldenström
macroglobulinemia,
n [ 12
CLL/lymphocytic
lymphoma,
n [ 10
Low-grade
NHL, n [ 6
DLBCL,
n [ 6
Membranoproliferative
glomerulonephritis
(n ¼ 3)
1 1 1 0
Minimal-change disease
(n ¼ 2)
1 1 0 0
Membranous
nephropathy (n ¼ 1)
0 1 0 0
Focal segmental
glomerulosclerosis
(n ¼ 1)
0 0 0 1
Light chain deposition
disease (n ¼ 1)
1 0 0 0
IgA nephropathy (n ¼ 1) 0 0 1 0
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; NHL, non-
Hodgkin lymphoma.
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This study on a large cohort of patients with B-cell
lymphoproliferative syndrome and biopsy-proven
renal involvement shows that all lymphoproliferativeTable 4. Renal pathologic findings in lymphoma-associated disorders
Whole population
(n [ 34)
Waldenströ
Light microscopy
Sclerotic glomeruli 10 (29.4)
Mesangial hypertrophy/hypercellularity 7 (20.6)
Endocapillary proliferation 2 (5.9)
Glomerular thrombi 2 (5.9)
Specific glomerular lesions 9 (26.5)
Interstitial fibrosis 20 (58.8)
Lymphomatous interstitial infiltration 33 (97.1)
Focala 14 (42.4)
Diffusea 19 (57.6)
Epithelioid and gigantocellular non-necrotizing granuloma 3 (8.8)
Tubular atrophy/sclerosis 17 (50.0)
Acute tubular necrosis 9 (26.5)
Vascular sclerotic lesions 10 (29.4)
Composition of deposits by immunofluorescence
Light chain
Kappa 12 (35.3)
Lambda 9 (26.5)
Negative 5 (14.7)
Unknown 8 (23.5)
Ig
IgM 9 (26.5)
IgG 2 (5.9)
IgA 9 (26.5)
C3 and/or C1q 17 (50.0)
Unknown 9 (26.5)
Ultrastructural studies
Yes 2 (5.9)
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin
aPercentages are calculated into the subgroup.
Qualitative data: frequency (%).
Kidney International Reports (2019) 4, 688–697disorders can lead to renal lesions, predominantly
infiltration, that may coexist with other glomerular,
tubular, and vascular kidney lesions. The most
important finding is that the clinical and laboratory
presentation did not allow predicting the renal
involvement. Consequently, currently, only kidney
biopsy can significantly improve the diagnosis, prog-
nosis, and therapeutic decision-making for these pa-
tients. Similarly, the hematological response did not
consistently predict the renal response, possibly due to
the presence also of noninfiltrative renal lesions.
Indeed, when B-cell lymphoproliferative syndrome was
involved in renal dysfunction, the kidney biopsy
almost always revealed renal infiltration that could
explain the high frequency of AKI in our cohort (or in
these patients if it is a general finding). It also high-
lighted the frequent concomitant presence of tubular or
glomerular lesions, related to the lymphoma or its
consequences (e.g., hypercalcemia), or to preexisting
chronic injuries (e.g., vascular or glomerular sclerosis).
These underlying chronic lesions could limit the renal
response to the hematological treatment. Kowalewskam macroglobulinemia
(n [ 12)
CLL/Lymphocytic lymphoma
(n [ 10)
Low-grade NHL
(n [ 6)
DLBCL
(n [ 6)
6 (50.0) 2 (20.0) 1 (16.7) 1 (16.7)
3 (25.0) 2 (20.0) 2 (33.3) 0
1 (8.3) 1 (10.0) 0 0
1 (8.3) 0 1 (16.7) 0
3 (25.0) 3 (30.0) 2 (33.3) 1 (16.7)
9 (75.0) 7 (70.0) 3 (50.0) 1 (16.7)
12 (100.0) 9 (90.0) 6 (100.0) 6 (100.0)
4 (33.3) 5 (55.6) 4 (66.7) 1 (16.7)
8 (66.7) 4 (44.4) 2 (33.3) 5 (83.3)
0 3 (30.0) 0 0
8 (66.7) 6 (60.0) 2 (33.3) 1 (16.7)
5 (41.7) 3 (30.0) 1 (16.7) 0
6 (50.0) 3 (30.0) 0 1 (16.7)
8 (66.6) 2 (20.0) 2 (33.3) 0
2 (16.7) 5 (50.0) 2 (33.3) 0
2 (16.7) 2 (20.0) 0 (0.0) 1 (16.7)
0 (0.0) 1 (10.0) 2 (33.3) 5 (83.3)
7 (58.3) 0 1 (16.7) 1 (16.7)
1 (8.3) 1 (10.0) 0 0
4 (33.3) 4 (40.0) 1 (16.7) 0
8 (66.7) 6 (60.0) 2 (33.3) 1 (16.7)
0 2 (20.0) 2 (33.3) 5 (83.3)
0 2 (20.0) 0 0
lymphoma.
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Table 5. Comparison between renal responder and renal non-responder patients
Variable All patients (n [ 29)
Renal response
PYes (n [ 8) No (n [ 21)
Sex ratio 29 8 21 0.635
Male/Female 22/7 (75.9%, 24.1%) 7/1 (87.5%/12.5%) 15/6 (71.4%/28.6%)
Age $70 yr 17 (58.6%) 4 (50.0%) 13 (61.9%) 0.683
Performance status > 2 3 (10.3%) 1 (12.5%) 2 (9.5%) 1.000
Renal function impairment
Acute kidney injury 20 (69.0%) 6 (75.0%) 14 (66.7%) 1.000
Serum creatinine >300 mmol/l 10 (34.5%) 1 (12.5%) 9 (42.9%) 0.201
Inaugural renal impairment 10 (34.5%) 4 (50.0%) 6 (28.6%) 0.390
Preexisting nephropathy 14 (48.3%) 2 (25.0%) 12 (57.1%) 0.215
Morphological abnormalities 9 (31.0%) 3 (37.5%) 6 (28.6%) 0.675
Non-kidney localizations
1 or 2 sites 4 (13.8%) 0 4 (19.0%) 0.552
>2 sites 17 (58.6%) 7 (87.5%) 10 (47.6%) 0.093
Hematological parameters
Anemia <10 g/dl 16 (55.2%) 3 (37.5%) 13 (61.9%) 0.406
Bone marrow involvement 22 (84.6%) 4 (66.7%) 18 (90.0%) 0.218
Elevated LDH 9 (34.6) 4 (50.0) 5 (27.8) 0.382
Urinalysis
Proteinuria >1 g/l 12 (46.2) 2 (40.0) 10 (47.6) 1,000
Nephrotic syndrome 4 (13.8) 2 (25.0) 2 (9.5) 0.300
Hematuria 12 (50.0) 2 (40.0) 10 (52.6) 1.000
Renal histology
Fibrosis > 50% 6 (20.7) 0 6 (28.6) 0.148
Tubular atrophy 16 (55.2) 3 (37.5) 13 (61.9) 0.406
Vascular lesions 10 (34.5) 2 (25.0) 8 (38.1) 0.675
Ischemic chronic glomerular lesions 10 (34.5) 2 (25.0) 8 (38.1) 0.675
Diagnosis 0.007
CLL/lymphocytic lymphoma 10 (34.5) 4 (50.0) 6 (28.6)
Low-grade NHL 5 (17.2) 0 5 (23.8)
DLBCL 3 (10.3) 3 (37.5) 0
Waldenström macroglobulinemia 11 (37.9) 1 (12.5) 10 (47.6)
Hemopathy prior to PKB 19 (65.5) 4 (50.0) 15 (71.4)
Hematological response 0.417
Complete response 14 (48.3) 5 (62.5) 9 (42.9)
Partial response 4 (13.8) 0 4 (19.0)
Unevaluable 4 (13.8) 1 (12.5) 3 (14.3)
Progressive disease 6 (20.7) 1 (12.5) 5 (23.8)
Stability 1 (3.4) 1 (12.5) 0
End of follow-up
Death 10 (34.5) 1 (12.5) 9 (42.9) 0.201
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; NHL, non-Hodgkin lymphoma; PKB, percutaneous kidney biopsy.
Qualitative data: frequency (%).
CLINICAL RESEARCH L Corlu et al.: Renal Dysfunction With Direct Infiltrationet al.8 also found no direct correlation between AKI
and the type of detected renal lesions, although pro-
teinuria was correlated with glomerular injury,
differently from our study, possibly due to the smaller
population. Like in plasma cell dyscrasia, PKB seems
essential for the characterization of the renal lesions
and fibrosis that might influence the kidney function
prognosis. Renal dysfunction can occur at the begin-
ning of the disease (PKB revealed the hematological
disease in 38.2% of our patients), or after a long pro-
gression of the primary lymphoma (maximum 20
years).8 Moreover, in the case of hematological694neoplasm relapse, PKB remains useful to differentiate
active lesions from fibrotic lesions that could explain
CKD persistence.
The histological features of our cohort are consistent
with the literature data, with a monotypic B-cell infil-
trate reaching the interstitium in most patients
(97.1%). This infiltrate was mostly diffuse rather than
focal, with a focal nodular aspect preferentially found
in low-grade lymphomas. Previous studies reported
that the renal infiltrate is rather focal in lympho-
plasmacytic lymphoma, and diffuse and massive in
chronic lymphocytic leukemia.8,20 In our study, theKidney International Reports (2019) 4, 688–697
Figure 2. Kaplan-Meyer survival curve. CI, confidence interval.
L Corlu et al.: Renal Dysfunction With Direct Infiltration CLINICAL RESEARCHseverity of the initial renal involvement seemed to be
correlated with the extent of the lymphomatous infil-
trate. This is consistent with other studies, with a
serum creatinine level higher than 350 mmol/l in the
case of diffuse infiltrate and not exceeding 245 mmol/l
in the case of focal infiltrate.21 The high rate of inter-
stitial infiltrate in our cohort compared with previous
studies could be explained by the different inclusion
criteria. For instance, Strati et al.9 described patients
with chronic lymphocytic leukemia or monoclonal B-
cell lymphomatosis who underwent kidney biopsy for
renal failure and found a lower rate of infiltrative le-
sions and some lesions not related to the hematological
disorder. On the other hand, Chauvet et al.10 found that
interstitial diffuse infiltration was common, even in
renal disorders associated with IgM monoclonal gam-
mopathies. Higgins et al.11 included patients with
monoclonal IgM protein and availability of a kidney
and a bone marrow biopsy, leading to more diverse
kidney lesions.
In our cohort, 9 of 34 patients had glomerular lesions
(10 of 55 patients in the study by Törnroth et al.5 and
10 of 18 in the study by Kowalewska et al.8). Different
glomerular lesions can be associated with non-Hodgkin
lymphoma, among which membranoproliferative
glomerulonephritis and membranous nephropathy are
the most common,8,9 whereas minimal-change lesions
are uncommon, differently from Hodgkin disease.22,23
Therefore, the main challenge is to determine the link
with the hematological disorder.24 The definition of
paraneoplastic glomerulopathy is based on its chro-
nology, previous pathophysiological suspicion, and
concomitant changes of the glomerulopathy and
hemopathy on treatment.Kidney International Reports (2019) 4, 688–697Radiological investigations identified kidney anom-
alies only in one-third of our cohort, although all pa-
tients had a histologically proven renal involvement.
Contrast-enhanced CT remains the best examination if
renal involvement is suspected, but with high risk of
renal toxicity.25,26 Some authors suggested using
magnetic resonance imaging, especially in patients with
preexisting CKD.27 The most commonly described
morphological abnormalities are multiple parenchymal
kidney masses.28 In our study, only 2 patients (5.9%)
presented a typical bilateral kidney enlargement,
compared with 21% (n ¼ 4/19) in the study by Aymard
et al.20 Extrarenal localization was found in most pa-
tients in our study (74%), whereas Törnroth et al.5
reported extrarenal involvement in 44% of patients
at biopsy time (especially in retroperitoneal lymph
nodes). Discrepancies between the radiological and
histological findings can be explained by the lower
radiology tool sensitivity at the early stages of kidney
involvement when the organ morphology is still pre-
served,29 and the fact that the radiological picture of
renal lymphoma may overlap with that of other dis-
eases, for instance renal cancer or metastases from other
tumors.30 This could also explain the high variability of
renal lymphomatous involvement prevalence in the
literature, whereas postmortem analysis reported a
frequency ranging from 6% to 60%.2,12,13 The lower
sensitivity of radiological tools strengthens the impor-
tance of renal biopsy for diagnosis.
In our series, the information provided by PKB led
to treatment with corticosteroids or chemotherapy in
most patients (85%), as previously reported (95% in
the study of Aymard et al.,20 82% for Törnroth et al.5).
PKB allowed starting treatment earlier (within fewer
than 15 days after PKB for 62% of patients). Renal
involvement did not seem to influence the chemo-
therapy choice, especially for aggressive subtypes (all
treated according to the standard recommendations),
although it is difficult to reach robust conclusions due
to the heterogeneity of the cohort and the changes in
clinical practices over time. As in the study by Higgins
et al.,11 the renal response was not always correlated
with the hematological response, probably because of
the presence of other renal lesions in addition to infil-
tration. Among the 72% of patients with an overall
hematological response (CR þ partial remission), only 1
of 3 showed RR. In the study by Canet et al.31 on 200
patients (53.5% with non-Hodgkin lymphoma), AKI
was associated with CR lasting less than 6 months
(39.4% vs. 68.3% without AKI, P < 0.01) and higher
mortality rate (47.4% vs. 30.2%, P < 0.01). The in-
dependent CR factors were age, high performance sta-
tus, number of organ dysfunctions, and AKI. Renal695
CLINICAL RESEARCH L Corlu et al.: Renal Dysfunction With Direct Infiltrationinsufficiency was an independent negative prognostic
risk factor in the series described by Strati et al.32
Finally, 23 of 34 patients had CKD at the last follow-
up. We tried to evaluate the risk factors associated with
CKD, such as age, severity of the initial renal
involvement, or abundance of interstitial infiltration.
The only prognostic factor of renal response remained
the lymphoma subtype, possibly because of the small
number of patients in each lymphoma group and
therefore the lack of statistical power. Patients with
high-grade lymphoma were exclusively in the RR
group (3 of 8 patients), probably related to their initial
clinical symptomatology that led to a faster diagnosis,
and therefore to earlier therapy, and their usually
higher chemosensitivity. In the study by Törnroth
et al.,5 43 of the 45 treated patients (95%) were RRs,
but their younger median age (45 years compared with
70 years in our study) might suggest fewer chronic
renal lesions. The overall survival in our series
remained good, and seemed to be correlated with the
hematological response, because only 1 of the 16 pa-
tients (6%) in the CR group died, compared with 8 of
the 11 patients (73%) in the partial response group or
with hematological progression.
Our study presents a selection bias because it
included only patients with PKB and the “lymphoma”
code in the pathology database, possibly explaining the
high rate of renal infiltration in our series.8 Each study
has his own bias, according to the inclusion criteria,
making comparisons between series difficult.10,32 For
example, Chauvet et al.10 or Higgins et al.11 included
patients with monoclonal IgM-secreting B-cell lym-
phoproliferative disorders, whereas in our study only
approximately one-half of the patients had monoclonal
gammopathy. It also presents a bias of interpretation
because patients with different lymphoma subtypes
were included in a single group, although they could
have had specific features that could not be identified
because of the small size of each subgroup. Moreover,
electron microscopy analysis was performed only in w
biopsies, although it could have been of great interest
for a precise characterization of the deposits. Large
descriptive studies are needed to better identify the
characteristics of the renal involvement in each of these
lymphoma types.CONCLUSION
Renal involvement in patients with B-cell lymphoma
can lead to kidney dysfunction of varying severity
through various mechanisms, and remains a major
cause of morbidity and mortality. Like for plasma cell
dyscrasia, in addition to blood and urine analyses
(serum ionogram, creatinine, urine phosphate and696calcium, proteinuria with electrophoresis, and urine
cytology), kidney biopsy is important to confirm the
diagnosis and to visualize the specific or nonspecific
acute and/or chronic kidney lesions for rapid treatment
initiation. Therefore, it should be proposed at diagnosis
of each hemopathy showing radiological or biological
signs of renal damage to better preserve the patients’
renal function and improve their long-term survival.DISCLOSURE
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